帕金森病患者血清胶质纤维酸性蛋白的对照研究

目的探讨帕金森病患者血清胶质纤维酸性蛋白（GFAP）的浓度变化及其临床意义。方法用ELISA法检测帕金森病组（23例）、健康对照组（29例）和急性脑梗死组（30例）共82例受试者血清GFAP含量并进行比较。帕金森病组根据病程又分为两组，即病程〈5年组和病程≥5年组，了解帕金森病患者病程和年龄对血清GFAP含量的影响。结果帕金森病组、急性脑梗死组血清GFAP含量分别为（1．628±0．104）μg/L，（1．637±0．063）μg／L]较健康对照组（0．025±0．003）μg／L]明显升高（t值分别为82．7，143．2，均P〈0．05），而帕金森病组和急性脑梗死组血清GFAP含量差异无统计学意义（t=0．214，P〉0．05）。帕金森病组血清GFAP含量和年龄无相关性，帕金森病患者不同病程组间血清GFAP含量差异无统计学意义（P〉0．05）。结论帕金森病患者血清中GFAP含量明显增加，但没有疾病特异性，随病程的延长帕金森病患者血清GFAP含量保持一定水平，提示星形胶质细胞在疾病过程中的作用持续存在。

Changes and significance of serum glial fibrillary acidic protein (GFAP) in patients with Parkinson disease

Objective To investigate changes in serum level of glial fibrillary acidic protein (GFAP) in patients with Parkinson disease (PD) and its clinical significance. Methods Serum GFAP was determined with sandwich ELISA for 82 patients with PD and acute cerebral infarction (ACI), as well as healthy normal controls. Patients with PD were then divided into two sub-groups in terms of their course duration, one with less than five years and the other with more than or equal to five years. Effects of course duration and age of the patients on their serum GFAP were analyzed. Results Serum level of GFAP was significantly higher in patients with PD (1.628±0.104) μg/L] and ACI (1. 637±0. 063 )μg/L] than that in healthy normal controls (0. 025±0. 003)μg/L, t = 82. 7, 142. 2, all P <0. 05 ]. But, there was no significant difference in serum GFAP between patients with PD and ACI ( t =0. 214, P > 0. 05 ). Serum level of GFAP in PD patients had no significant correlation with their age. There was no significant difference in serum GFAP between two sub-groups of patients with PD (P > 0.05 ). Conclusions Serum level of GFAP increased significantly in PD patients, as compared to healthy normal controls, but it is not specific. Serum GFAP in patients with PD maintained at certain high level with progression of the disease, indicating effect of astrocytes may persistently exist during the disease course.